GOODIX
Goodix (Shanghai Stock Exchange:603160), the premier developer of human interface and biometric solutions for mobile devices, announced today that Huawei P10 and P10 Plus, flagship smartphones of 2017 just launched at Mobile World Congress 2017, are using Invisible Fingerprint Sensor (IFS™) from Goodix.
Huawei’s P10 and P10 Plus smartphones have stylish, integrated screen panel design. The Home key has IFS™ embedded under the screen panel, allowing fingerprint authentication through the glass. IFS™ from Goodix enables the elegant and slim design of P10 and P10 Plus while providing secure and easy-to-use fingerprint authentication. This safeguards the smartphone and secures mobile transactions.
World’s first IFS™ solution meets Huawei’s design needs
Traditionally, a button needs to be placed on the front or at the back of a smartphone in order to install a fingerprint sensor. This means manufacturers need to open a hole on the glass panel for the button. This occupies space, affects the overall phone design and increases the complexity of manufacturing process. Goodix’s IFS™ addresses these issues by seamlessly integrating the sensor right under the glass panel without the need to drill a hole and place a button.
Goodix and Huawei share the same vision of innovating latest technologies to fulfill people’s desires and needs. The longstanding partnership between the two companies is a great success. Prior to the P10 and P10 Plus, a number of Huawei smartphones already use various Goodix’s fingerprint authentication and touchscreen controller solutions. The two companies will continue to innovate to provide safer, more convenient and intelligent technology to mobile users.
IFS™ gives manufacturers more flexibility to develop stylish, slim phone designs. It also supports thick glass panels and improves the water and dust resistance. All this combines to deliver a better user experience and higher reliability.
From R&D to successful commercialization
To authenticate fingerprints through glass panels poses many technical challenges and requires the redesign of circuits and the software algorithm. Goodix has been driving the development process from R&D to commercialization. Since IFS™ was launched in 2014, the company has worked closely with glass panel manufacturers and fingerprint module suppliers to ensure that the functionality, performance, reliability and supply of IFS can meet the various demands of mobile device manufacturers.
The successful commercialization of IFS™ reinforces Goodix as a global leader in biometric technology. This leading position is well recognized by global mobile brands. As of January 2017, Goodix has applied for and received more than 900 patents. The strong R&D capability propels Goodix forward to continue to innovate for mobile users. IFS™ won a Consumer Electronics Show (CES) Innovation Award in 2016, and Goodix was the first Chinese integrated circuit (IC) company to ever win this honor.
About Goodix:
Goodix , a premier developer and provider of fingerprint and touchscreen solutions for mobile phones, tablets and wearables, currently holds a diversified portfolio of fingerprint authentication solutions that provides excellent flexibility to suit the varying preferences from consumers and partners such as Live Finger Detection™, Invisible Fingerprint Sensor (IFS™), Glass-covered and Coating button sensors. In addition, Goodix has been actively involved in assisting Alipay and China UnionPay with reviewing industry standards for fingerprint authentication. An increasing number of top-tier handset manufacturers adopting fingerprints and touch solutions from the company. On October 17, 2016, Goodix was listed on the Shanghai Stock Exchange, the stock code is 603160.
Goodix™ and Invisible Fingerprint Sensor (IFS™) are trademarks of Goodix in China and other countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170227006232/en/
Contact:
FleishmanHillard, on behalf of Goodix
Alisa Davis, 415-318-4086
Alisa.davis@fleishman.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom